Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CtDNA-guided Adjuvant Chemotherapy in Elderly Colon Cancer
NCT06609551Phase 3Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2029
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, capecitabine and oxaliplatin in colon cancer (4 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Disease-Free Survival at 2 years. Started Jul 2024; status: recruiting.
02
Drugs
fluorouracilcapecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06609551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609551.